Cedazuridine; Decitabine Patent Expiration
Cedazuridine; Decitabine is Used for treating patients with CDA deficiency. It was first introduced by Taiho Oncology Inc
Cedazuridine; Decitabine Patents
Given below is the list of patents protecting Cedazuridine; Decitabine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inqovi | US11963971 | Combination decitabine and cedazuridine solid oral dosage forms | Feb 24, 2041 | Taiho Oncology |
| Inqovi | US12195496 | 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same | Oct 07, 2040 | Taiho Oncology |
| Inqovi | US8268800 | Certain compounds, compositions and methods | Aug 22, 2030 | Taiho Oncology |
| Inqovi | US8618075 | Certain compounds, compositions and methods | Oct 16, 2028 | Taiho Oncology |
| Inqovi | US9567363 | Certain compounds, compositions and methods | Oct 16, 2028 | Taiho Oncology |
Cedazuridine; Decitabine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List